CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 119 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00455975
NCT00455975Phase 2Completed
CompareCT.gov

Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma

SCRI Development Innovations, LLC·interventional·Posted Apr 4, 2007·Updated Dec 22, 2014

In Brief

A Phase 2 clinical trial evaluating Bevacizumab for Renal Cancer and Kidney Cancer. Completed, enrolled 119 participants across 13 sites.

Detailed Summary

This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cancer, Kidney Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 4, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJul 1, 2013
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 19.2 years ago

Interventions

Bevacizumabdrug

Bevacizumab